Endothelial dysfunction in children with Crohn´s disease – a combined diagnostic approach
Authors:
A. Masopustová 1; P. Jehlička 1; J. Sýkora 1; M. Huml 1; J. Schwarz 1; L. Trefil 2
Authors‘ workplace:
Dětská klinika FN, Univerzita Karlova v Praze, Lékařská fakulta v Plzni
přednosta prof. MUDr. J. Sýkora, Ph. D.
1; Ústav klinické biochemie a hematologie FN, Univerzita Karlova v Praze, Lékařská fakulta v Plzni
přednosta prof. MUDr. J. Racek, DrSc.
2
Published in:
Čes-slov Pediat 2015; 70 (1): 3-8.
Category:
Original Papers
Overview
Inflammatory bowel disease (IBD) is associated with a higher risk of cardiovascular disorders in adults, although there are still very sporadic published data in children. The objective of our prospective study was to evaluate endothelial dysfunction (ED) by reactive hyperaemia index (RHI) and specific biochemical parameters in children with Crohn´s disease (CD).
21 CD patients and 12 healthy children were enrolled in the study. Diagnosis of CD was based on clinical, endoscopic and histological criteria including the Paediatric Crohn´s disease Activity Index (PCDAI). ED was assessed using the combination of RHI and specific biochemical markers.
We found significantly lower RHI values in CD patients in comparison to the healthy controls (p<0,05). E-selectin (p<0.05), asymmetric dimethylarginine (p<0.01) and high-sensitive CRP (p<0.05) were significantly increased in CD patients compared to the control group.
Our results demonstrate that Crohn´s disease might be associated with ED and therefore with a higher risk of development of premature atherosclerosis. We also demonstrated the suitability of using the combination of RHI and specific biochemical markers in assessing ED and stratifying of cardiovascular risk and long term follow-up in children with CD.
Key words:
endothelial dysfunction, children, reactive hyperaemia index, asymmetric dimethylarginine, Crohn´s disease
Sources
1. Behr MA. The path to Crohn’s disease: Is mucosal pathology a secondary event? Inflamm Bowel Dis 2010; 16: 896–902.
2. Cromer W, Mathis JM, Granger DN, et al. Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol 2011; 17: 578–593.
3. Dharmam P, Chadee K. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key. Curr Mol Pharmacol 2008; 1: 195–212.
4. Oshma T, laroux FS, Coe LI, et al. Interferon-gamma and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function. Microvasc Res 2001; 61: 130–143.
5. Kayahan H, Sari I, Cullu N, et al. Evaluation of early atherosclerosis in patients with inflammatory bowel disease. Dig Dis Sci 2012; 57: 2137–2143.
6. Mori M, Stokes KY, Vowinkel T, et al. Colonic blood flow responses in experimental colitis: time course and underlying mechanisms. Am J Physiol Gastrointest Liver Physiol 2005; 289: G1024–1029.
7. Hamburg NM, Keyes MJ, Larson MG, et al. Cross sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008; 13: 2467–2474.
8. Morrison KM, Dyal L, Conner W, et al. Cardiovascular risk factors and non-invasive assessment of subclinical atherosclerosis in youth. Atherosclerosis 2010; 208: 501–505.
9. Bonetti PO, Pumper GM, Higano ST, et al. Non-invasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperaemia. J Am Coll Cardiol 2004; 44: 2137–2141.
10. Adamska I, Czerwionka-Szaflarska M, Kulwas A, et al. Value of E-selectin and L-selectin determination in children and youth with inflammatory bowel disease. Med Wieku Rozwoj 2007; 11: 413–418.
11. Nakamura S, Ohtani H, Watanabe Y, et al. In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells. Lab Invest 1993; 69: 77–85.
12. Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2010; 16: 52–57.
13. Aloi M, Tromba L, Di Nardo G, et al. Premature subclinical atherosclerosis in pediatric inflammatory bowel disease. J Pediatr 2012; 161: 589–594.
14. IBD Working group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for the diagnosis – the Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41: 1–7.
15. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr 1991; 12: 439–447.
16. Levine A., Griffiths A., Markowitz J., et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17: 1314–1321.
17. Schinzari F, Armuzzi A, De Pascalis B, et al. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn’s disease. Clin Pharmacol Ther 2008; 83: 70–76.
18. Murdaca G, Colombo BM, Cagnati P, et al. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012; 224: 309–317.
19. Satoh M. Endothelial dysfunction as an underlying pathophysiological condition of chronic kidney disease. Clin Exp Nephrol 2012; 16: 518–521.
20. Zhang CY, Lu LJ, Li FH, et al. Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients. J Clin Rheumatol 2009; 15: 111–116.
21. Piccione MC, Bagnato G, Zito C, et al. Early identification of vascular damage in patients with systemic sclerosis. Angiology 2011; 62: 338–343.
22. Meyer MF, Lieps D, Schatz H, et al. Influence of the duration of type 2 diabetes on early functional and morphological markers of atherosclerosis compared to the impact of coexisting classic cardiovascular risk factors. Exp Clin Endocrinol Diabetes 2008; 116: 298–304.
23. Turemen EE, Cetinarslan B, Sahin T, et al. Endothelial dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to autoimmune thyroiditis. Endocrine Journal 2011; 58: 349–354.
24. Jehlička P, Stožický F, Mayer O Jr, et al. Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1. Physiol Res 2009; 58: 179–184.
25. Onkelinx S, Cornelissen V, Goetschalckx K, et al. Reproducibility of different methods to measure the endothelial function. Vasc Med 2012; 17: 79–84.
26. Al-Qaisi M, Kharbanda RK, Mittal TK, Donald AE. Measurement of endothelial function and its clinical utility for cardiovascular risk. Vasc Health Risk Manag. 2008; 4: 647–52.
27. Moerland M, Kales AJ, Schrier L, et al. Evaluation of the EndoPAT as a tool to assess endothelial function. Int J Vasc Med 2012; 2012: 904141.
28. Maharshak N, Arbel Y, Bornstein NM, et al. Inflammatory bowel disease is not associated with increased intimal media thickening. Am J Gastroenterol 2007; 102: 1050–1055.
29. Broide E, Schopan A, Zaretsky M, et al. Intima-media thickness of the common carotid artery is not significantly higher in Crohn’s disease patients compared to healthy population. Dig Dis Sci 2011; 56: 197–202.
30. Osika W, Montgomery SM, Dangardt F, et al. Anger, depression and anxiety associated with endothelial function in childhood and adolescence. Arch Dis Child 2011; 96: 38–43.
31. Jehlička P, Huml M, Schwarz J, et al. Reactive hyperaemia index as a marker of endothelial dysfunction in children with Crohn´s disease is significantly lower that healthy controls. Acta Paediatrica 2014; 103: e 55–e 60.
32. Jehlička P, Huml M, Votava T, et al. Reaktivní hyperemický index v detekci endoteliální dysfunkce u dětí – pilotní studie. Čes-slov Pediat 2011; 66: 76–79.
Labels
Neonatology Paediatrics General practitioner for children and adolescentsArticle was published in
Czech-Slovak Pediatrics
2015 Issue 1
Most read in this issue
- Rhabdomyolysis after heavy physical exercise at the fithess center
- Primary Care Paediatricians (PCP) and their options in providing services to newborns, infants, children and adolescent patients
- Renal cysts and diabetes syndrome
- Malignant tumours of thyroid gland in children